Insider Trading Alert - OHI, AMSG And PODD Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 6, 2015, 74 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $199.44 to $8,899,995.42.

Highlighted Stocks Traded by Insiders:

Omega Healthcare Investors (OHI) - FREE Research Report

Korman Bernard J, who is Director at Omega Healthcare Investors, bought 100,000 shares at $35.99 on May 6, 2015. Following this transaction, the Director owned 710,057 shares meaning that the stake was boosted by 16.39% with the 100,000-share transaction.

The shares most recently traded at $35.03, down $0.96, or 2.75% since the insider transaction. Historical insider transactions for Omega Healthcare Investors go as follows:

  • 4-Week # shares bought: 32,424
  • 4-Week # shares sold: 18.0 million
  • 12-Week # shares bought: 32,424
  • 12-Week # shares sold: 18.0 million
  • 24-Week # shares bought: 32,424
  • 24-Week # shares sold: 18.0 million

The average volume for Omega Healthcare Investors has been 1.9 million shares per day over the past 30 days. Omega Healthcare Investors has a market cap of $6.5 billion and is part of the financial sector and real estate industry. Shares are down 9.52% year-to-date as of the close of trading on Wednesday.

Omega Healthcare Investors, Inc. is a real estate investment firm. The firm invests in the real estate markets of United States. It invests in healthcare facilities, primarily in long-term healthcare facilities in order to create its portfolio. Omega Healthcare Investors, Inc. The stock currently has a dividend yield of 6.11%. The company has a P/E ratio of 22.0. Currently, there are 3 analysts who rate Omega Healthcare Investors a buy, 2 analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OHI - FREE

TheStreet Quant Ratings rates Omega Healthcare Investors as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Omega Healthcare Investors Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Amsurg (AMSG) - FREE Research Report

Holden Christopher A, who is President and CEO at Amsurg, sold 3,000 shares at $62.91 on May 6, 2015. Following this transaction, the President and CEO owned 294,496 shares meaning that the stake was reduced by 1.01% with the 3,000-share transaction.

The shares most recently traded at $64.76, up $1.85, or 2.85% since the insider transaction. Historical insider transactions for Amsurg go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 24,097
  • 24-Week # shares sold: 27,097

The average volume for Amsurg has been 387,800 shares per day over the past 30 days. Amsurg has a market cap of $3.0 billion and is part of the health care sector and health services industry. Shares are up 14.27% year-to-date as of the close of trading on Wednesday.

AmSurg Corp., through its subsidiaries, provides ambulatory and physician services in the United States. The company operates through two divisions, Ambulatory Services and Physician Services. The company has a P/E ratio of 48.9. Currently, there are 8 analysts who rate Amsurg a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMSG - FREE

TheStreet Quant Ratings rates Amsurg as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, good cash flow from operations and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Amsurg Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Insulet (PODD) - FREE Research Report

Thomas Bradley A, who is EVP Human Resources at Insulet, bought 1,000 shares at $27.26 on May 6, 2015. Following this transaction, the EVP Human Resources owned 31,486 shares meaning that the stake was boosted by 3.28% with the 1,000-share transaction.

Ryan Patrick, who is Chief Operating Officer at Insulet, bought 3,669 shares at $26.99 on May 6, 2015. Following this transaction, the Chief Operating Officer owned 47,990 shares meaning that the stake was boosted by 8.28% with the 3,669-share transaction.

The shares most recently traded at $26.77, down $0.22, or 0.82% since the insider transaction. Historical insider transactions for Insulet go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 3,372
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 16,879
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 16,879

The average volume for Insulet has been 864,700 shares per day over the past 30 days. Insulet has a market cap of $1.5 billion and is part of the health care sector and health services industry. Shares are down 42.66% year-to-date as of the close of trading on Wednesday.

Insulet Corporation develops, manufactures, and sells insulin infusion systems for people with insulin-dependent diabetes in the United States. Currently, there are 7 analysts who rate Insulet a buy, 1 analyst rates it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PODD - FREE

TheStreet Quant Ratings rates Insulet as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, generally high debt management risk, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Insulet Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists